A member of this family, BCL2A1, was shown to be amplified in 30% of melanoma and contribute to resistance to BRAF inhibition [62] (see section “Intrinsic Resistance to BRAF and MEK Inhibitors”). This evidence concerns the gene BRAF and melanoma.